Company will use XmAb to enhance the therapeutic properties of its antibody candidates.
Xencor reported a collaboration with Boehringer Ingelheim to optimize therapeutic Mabs with improved clinical performance. Boehringer Ingelheim will apply Xencor’s XmAb™ technology platform, including Fc domains, to maximize the efficacy of its antibody drug candidates against selected targets of interest.
Xencor says its XmAb Fc domains are designed to enhance the therapeutic properties of antibodies, including sustained half-life, increased structural stability, and greater potency.
Under the terms of the agreement, Xencor will receive an upfront payment and is eligible to receive additional license fees, milestones, and a royalty payment on any products commercialized by Boehringer Ingelheim that incorporate its technology.